# The neonatal lung microbiome: a dynamic determinant of respiratory health, disease, and novel therapeutics

**Authors:** Wanwei Zheng, Yan Liang, Jiayao Li

PMC · DOI: 10.3389/fped.2026.1770578 · Frontiers in Pediatrics · 2026-03-16

## TL;DR

The neonatal lung microbiome influences respiratory health and disease, offering new diagnostic and therapeutic opportunities.

## Contribution

This review evaluates the microbiome's role in neonatal respiratory disorders and explores novel microbiome-targeted therapies.

## Key findings

- The neonatal lung microbiome interacts with the gut-lung axis to modulate immunity and inflammation.
- Multi-omics approaches reveal disease-specific microbiome signatures and pathways.
- Probiotics, phage therapy, and bacterial lysates show potential as therapeutic strategies for neonatal respiratory diseases.

## Abstract

The neonatal lung, once considered sterile, is now recognized to harbor a dynamic and complex microbiome that plays a critical role in respiratory health and disease. This review synthesizes current evidence on the composition, development, and functional impact of the lung microbiome in neonates, with a focus on its involvement in key respiratory disorders such as bronchopulmonary dysplasia, respiratory syncytial virus infection, neonatal acute respiratory distress syndrome, cystic fibrosis, and asthma predisposition. We place particular emphasis on the bidirectional communication along the gut-lung axis as a central mechanism, wherein intestinal microbiota and their metabolites modulate pulmonary immunity and inflammation. Emerging multi-omics studies that integrate microbial data with host metabolomic and immune profiles are highlighted for their role in deciphering disease-specific dysbiotic signatures and mechanistic pathways. Critically, this review advances the discussion beyond association by evaluating the translational potential of the microbiome as both a diagnostic biomarker and a therapeutic target. We provide a critical appraisal of innovative microbiome-targeted strategies—including probiotics, postbiotics, phage therapy, and bacterial lysates—and discuss the unique challenges and future directions for translating these approaches into safe, effective clinical interventions for vulnerable neonates. By bridging foundational science with clinical implications, this work aims to inform the development of novel, ecology-informed therapeutics to prevent and mitigate neonatal respiratory diseases.

## Linked entities

- **Diseases:** bronchopulmonary dysplasia (MONDO:0019091), respiratory syncytial virus infection (MONDO:0001577), cystic fibrosis (MONDO:0009061), asthma (MONDO:0004979)

## Full-text entities

- **Diseases:** cystic fibrosis (MESH:D003550), respiratory disorders (MESH:D012131), inflammation (MESH:D007249), asthma (MESH:D001249), bronchopulmonary dysplasia (MESH:D001997), respiratory diseases (MESH:D012140), neonatal acute respiratory distress syndrome (MESH:D012127), respiratory syncytial virus infection (MESH:D018357)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13033698/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13033698/full.md

## References

76 references — full list in the complete paper: https://tomesphere.com/paper/PMC13033698/full.md

---
Source: https://tomesphere.com/paper/PMC13033698